Drugs / clodronate
clodronate
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00658268 | Mar 2008 → Aug 2017 | — | Region Skane | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06263517 | Oct 2023 → Jul 2025 | osteoarthritis, knee | SPA Società Prodotti Antibiotici S.p.A. | Unknown | No outcome recorded |
| Phase 34 trials · 2 missed | ||||||
| Phase 3 | NCT06055257 | Jan 2025 → Dec 2027 expected | osteoradionecrosis of the mandible | Sunnybrook Health Sciences Centre | Recruiting | No outcome recorded |
| Phase 3 | NCT01348243 | Oct 2011 → Mar 2013 | postmenopausal osteoporosis | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT00009945 | Jan 2001 → Mar 2011 | breast cancer | NSABP Foundation Inc | Completed | Missed primary |
| Phase 3 | NCT00003232 | Nov 1997 → May 2002 | prostate cancer | NCIC Clinical Trials Group | Completed | Missed primary |
| Comparator or background therapy3 trials | ||||||
| Phase 0 | NCT03803839 Comparator | Mar 2004 → Mar 2014 | osteoarthritis, hip | University of Oulu | Completed | No outcome recorded |
| Phase 3 | NCT00127205 Comparator | Jul 2005 → Dec 2017 | breast cancer | SWOG Cancer Research Network | Completed | Missed primary |
| — | NCT00877097 Comparator | Jul 1996 → Dec 2002 | osteoporosis | Kuopio University Hospital | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | clodronate | “either 800mg clodronate (Bonefos®, Leiras Ltd, Finland)” NCT00877097 ↗8“clodronate 1600 mg once daily (Monday to Friday)” NCT06055257 ↗ |
| Known as | Bonefos | “either 800mg clodronate (Bonefos®, Leiras Ltd, Finland)” NCT00877097 ↗ |
| Known as | clodronate disodium | “Drug: clodronate disodium” NCT00127205 ↗ |
| Known as | clodronic acid | “Clodronic acid 100 mg/3,3 ml is used to prevent and treat postmenopausal osteoporosis.” NCT01348243 ↗ |
| Action | Inhibit | “tumor-induced osteoclastic resorption of bone, which may be inhibited by the antiosteolytic bisphosphonate clodronate” PMID 12149294 ↗ Aug 2002 |
| Modality | Small molecule | “the antiosteolytic bisphosphonate clodronate” PMID 12149294 ↗ Aug 2002 |
| Route | Intravenous | “clodronate 1,500 mg administered intravenously (IV)” PMID 12947070 ↗ Sep 2003 |